Abstract
Low molecular weight protamine (LMWP) appears to be a promising solution for heparin neutralization without the protamine-associated catastrophic toxic effects. The feasibility of this hypothesis was proven previously by using a peptide mixture produced from proteolytic digestion of protamine. To further examine the utility of this compound as an ultimate nontoxic protamine substitute, detailed studies on the purification and characterization of LMWP including the precise amino acid sequence, structure-function relationship, and possible mechanism were conducted. A number of LWMP fragments, composed of highly cationic peptides with molecular weights ranging from 700 to 1900 d, were prepared by digestion of native protamine with the protease thermolysin. These fragments were fractionated using a heparin affinity chromatography, and their relative binding strengths toward heparin were elucidated. Five distinct fractions were eluted at NaCl concentration ranging from 0.4 to 1.0 M and were denoted as TDSP1 to TDSP5, in increasing order of eluting ionic strength. Among these 5 fractions, TDSP4 and TDSP5 contained 3 LMWP peptide fragments, and they were found to retain the complete heparin-neutralizing function of protamine. By using a peptide mass spectrometry (MS) fingerprint mapping technique, the amino acid sequences of the microheterogeneous LMWP fragments in all these 5 elution fractions were readily identified. A typical structural scaffold made by arginine clusters in the middle and nonarginine residues at the N-terminal of the peptide sequence was observed for all these LMWP fragments. By aligning the sequences with the potency in heparin neutralization of these LMWP fragments, it was found that retention of potency similar to that of protamine required the presence of at least 2 arginine clusters in the LMWP fragments; such as the sequence of VSRRRRRRGGRRRR seen in the most potent LMWP fraction-TDSP5. The above finding was further validated by using a synthetic LMWP analogue-CRRRRRRR-and it was found that its heparin-neutralizing ability was increased by changing from a monomeric to a dimeric structure of this analogue peptide. Based on these results, the structural requirement for a compound to function as an effective heparin antidote and the possible mechanism involved in heparin neutralization were established.
KeyWords: Heparin LMWH neutralization, Protamine toxicity, LMWP peptide sequences, MS fingerprint mapping, Mechanism of heparin neutralization
References
- 1.Conrad SA, Rycus PT. Extracorporeal life support 1997. ASAIO J. 1998;44:848–852. doi: 10.1097/00002480-199811000-00016. [DOI] [PubMed] [Google Scholar]
- 2.Weiler JM, Gellhaus MA, Carter JG, et al. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy Clin Immunol. 1990;85:713–719. doi: 10.1016/0091-6749(90)90189-B. [DOI] [PubMed] [Google Scholar]
- 3.Hirsh J. Heparm. N Engl J Med. 1991;324:1565–1574. doi: 10.1056/NEJM199105303242206. [DOI] [PubMed] [Google Scholar]
- 4.Hirsh J, Dalen JE, Deykin D, Poller L. Heparin mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1992;102:337S–351S. doi: 10.1378/chest.102.4.337S. [DOI] [PubMed] [Google Scholar]
- 5.Katz NM, Kim YD, Siegelman R, Ved SA, Ahmed SW, Wallace RB. Hemodynamics of protamine administration. Comparison of right atrial, left atrial, and aortic injections. J Thorac Cardiovasc Surg. 1987;94:881–886. [PubMed] [Google Scholar]
- 6.Ovrum E, Lindberg H, Holen EA, Abdelnoor M. Hemodynamic effects of intraaortic versus intravenous protamine administration after cardiopulmonary bypass in man. Scand J Thorac Cardiovasc Surg. 1992;26:113–118. doi: 10.3109/14017439209099064. [DOI] [PubMed] [Google Scholar]
- 7.Neidhart PP, Meier B, Polla BS, Schifferli JA, Morel DR. Fatal anaphylactoid response to protamine after percutaneous transluminal coronary angioplasty. Eur Heart J. 1992;13:856–858. doi: 10.1093/oxfordjournals.eurheartj.a060271. [DOI] [PubMed] [Google Scholar]
- 8.Byun Y, Singh VK, Yang VC. Low molecular weight protamine: a potential nontoxic heparin antagonist. Thromb Res. 1999;94:53–61. doi: 10.1016/S0049-3848(98)00201-1. [DOI] [PubMed] [Google Scholar]
- 9.McKay DJ, Renaux BS, Dixon GH. Rainbow trout protamines. Amino acid sequences of six distinct proteins from a single testis. Eur J Biochem. 1986;158:361–366. doi: 10.1111/j.1432-1033.1986.tb09759.x. [DOI] [PubMed] [Google Scholar]
- 10.Hoffmann JA, Chance RE, Johnson MG. Purification and analysis of the major components of chum salmon protamine contained in insulin formulations using high-performance liquid chromatography. Protein Expr Purif. 1990;1:127–133. doi: 10.1016/1046-5928(90)90005-J. [DOI] [PubMed] [Google Scholar]
- 11.Rosenberg R. The heparin-antithrombin system: A natural anticoagulant mechanism. In: Colman RW, Marder VJ, Hirsh J, editors. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia, PA: JB Lippincott; 1987. pp. 1373–1392. [Google Scholar]
- 12.Shevchenko A, Loboda A, Shevchenko A, Ens W, Standing KG. Maldi quadrupole time-of-flight mass spectrometry: a powerful tool for proteomic research. Anal Chem. 2000;72:2132–2141. doi: 10.1021/ac9913659. [DOI] [PubMed] [Google Scholar]
- 13.Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis. 1989;9:21–32. doi: 10.1161/01.atv.9.1.21. [DOI] [PubMed] [Google Scholar]
- 14.Barrowcliffe TW, Mulloy B, Johnson EA, Thomas DP. The anticoagulant activity of heparin: measurement and relationship to chemical structure. J Pharm Biomed Anal. 1989;7:217–226. doi: 10.1016/0731-7085(89)80086-X. [DOI] [PubMed] [Google Scholar]
- 15.Lellouch AC, Lansbury PT. A peptide model for the heparin binding site of antithrombin iii. Biochemistry. 1992;31:2279–2285. doi: 10.1021/bi00123a010. [DOI] [PubMed] [Google Scholar]
- 16.Mulloy B, Forster MJ, Jones C, Davies DB. NMR and molecular-modelling studies of the solution conformation of heparin. Biochem J. 1993;293:849–858. doi: 10.1042/bj2930849. [DOI] [PMC free article] [PubMed] [Google Scholar]